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Background: Bronchial stenosis (BS) is currently found in 7–15% of lung transplanta-
tion (LT) recipients. Current treatment strategies have included Nd:Yag laser,
cryotherapy, bougie dilatation and stent placement. Bronchoscopic balloon dilata-
tion has been used as alternative treatment in a few cases with controversial results.
This is a study to prospectively assess the efficacy of bronchoscopic balloon
dilatation as a first step in the management of post-LT BS.
Methods: From January 1995 to December 2002, bronchoscopic balloon dilatation
was evaluated as first therapeutic option in all consecutive LT patients with BS.
Symptoms, pulmonary function tests, airway diameter and use of other therapeutic
techniques were evaluated.
Results: A total of 10 out of 284 anastomed airways (3.5%) in 9 out of 152 LT patients
were included in the study and follow-up lasted from 6 to 81 months. Dilatation of all
but one BS met with initial success: increase of both luminal dimensions and forced
vital capacity (P ¼ 0:01), and relief of symptoms. Bronchoscopic balloon dilatation
long-term follow-up showed effective results in 5 out of 10 (50%) bronchial stenoses,
after an average of 4 bronchoscopic balloon dilatation procedures (range 1–8). No
severe complications were observed. Stent placement was required in the other 5
bronchial stenoses.Elsevier Ltd. All rights reserved.
4932746138.
. De Gracia).
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J. De Gracia et al.28Conclusions: Bronchoscopic balloon dilatation is a safe method that should be
considered as first therapeutic treatment of post-LT BS. Its use avoids the need for
stent placement in up to 50% of cases.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Bronchial stenosis (BS) has been associated with
illnesses of several etiologies.1 Lung transplanta-
tion (LT), with an incidence of BS ranging from 7%
to 15% of cases, is currently one of the most
frequent causes.2 Management of BS of any
etiology, based on the application of cryotherapy,
laser therapy, bougie dilatation during rigid
bronchoscopy and stent placement, has displayed
its efficacy depending on the site and features of
the BS. Nevertheless, morbidity inherent or sec-
ondary to the procedure is frequent with these
techniques,2–8 especially secondary to stent place-
ment, the most commonly used treatment, where
complications have been observed in up to 75% of
cases.7,8 Bronchoscopic balloon dilatation (BBD) has
recently been used as alternative treatment in
retrospective studies,1–3,5,9,10 four of which were
performed only in LT recipients,2,3,5,10 with low
morbidity and limited efficacy. However, there are
no studies evaluating efficacy of BBD as the first
step in the management of these patients.
The aim of this study was to prospectively assess
the efficacy of BBD using fiberoptic bronchoscopy
(FOB) as definitive or contributing treatment of BS
after LT.Figure 1 Stenosis on intermedius bronchus.Patients and methods
From January 1995 to December 2002 all LT
recipients transferred from the intensive care unit
and diagnosed with BS by FOB were initially
included in the study. BBD was indicated as the
first therapeutic procedure in all patients with BS
of over 50% of bronchus diameter confirmed by
means of FOB. Patients with formal FOB contra-
indication or those not wishing to take part were
ruled out from the study.
Lung transplantation (LT)
LT, without revascularization procedures, were
performed as described previously.11 All patients
were on the same immunosuppression protocol
based on triple therapy with cyclosporine,
azathioprine and corticosteroids. Acute rejectionwas treated with pulse intravenous methylpredni-
solone for 3 days. Tacrolimus was included at the
initial immunosuppression in some cases or as
rescue therapy in patients with persistent or
recurrent rejection. Occasionally, mycophenolate
mofetil or methotrexate replaced azathioprine for
the same indication.
All cytomegalovirus-seropositive recipients re-
ceived ganciclovir prophylaxis for the first 45 days
or in the case of seronegative recipients with a
seropositive donor for 90 days. Similarly, all
patients were treated with nebulized amphotericin
B and oral cotrimoxazol prophylaxis three times a
week for life.BS diagnosis
All patients had BS of over 50% of bronchus
diameter confirmed by means of FOB (Fig. 1). Al
least one fiberoptic bronchoscopy was performed
on all patients prior to discharge. Additional FOBs
were indicated when respiratory symptoms were
present and/or pulmonary function tests were
suggestive of intrathoracic stenosis. Computed
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ally to evaluate the extent of the stenosis if
necessary.
Mild anastomotic ischemia12 was defined as
moderate to severe airway erythema with or
without mucosal friability or endobronchial plaques
without thick white exudates. Moderate anastomo-
tic ischemia was defined as thick white exudates or
a black eschar covering less than 25% of the
anastomotic circumference as viewed through the
bronchoscope. And finally, severe anastomotic
ischemia was defined as a black eschar covering
more than 25%.Figure 2 Balloon placement across the intermedius
bronchus stenosis.
Figure 3 Immediate increase of luminal dimensions of
the intermedius bronchus after bronchoscopic balloon
dilatation.Bronchoscopic balloon dilatation
FOB was always performed by the same operator as
previously described.13 In summary, 15min prior to
examination, 0.5mg of atropine was injected
subcutaneously. The upper airway was anesthetized
with 5mL of 1% lidocaine solution administered
orally by nebulization, and additional small quan-
tities of lidocaine were instilled through the
bronchoscope as required to control coughing.
FOB was carried out with fiberoptic bronchoscopes
Pentax EB-1830 and FB-19 TX (Asahi Optical Co.,
Ltd. Tokyo, Japan), and Olympus BF 1T160 (Olym-
pus America; Melville, NY). A variety of inflatable
balloons was used with diameters of 5–14mm and
lengths from 2 to 4 cm (Balloon dilatation catheter;
Medi-Techs; Boston Scientific Corporation, Water-
town, MA). Under bronchoscopic guidance, the
balloon was placed across the stenosis using an
adapted modification of Seldinger’s technique.14
Then, the balloon was gradually inflated with saline
solution using the basic inflation syringe to max-
imum balloon pressure psi and was held for 30 s
(Figs. 2 and 3). After deflation, if the airway was
still narrow, and if the patient tolerated the
dilatation with respect to oxygen saturation and
hemodynamics, the procedure was repeated either
with the same balloon or one with a larger
diameter. Monitoring FOB was carried out 2 and 6
weeks post dilatation, and fresh dilatation inter-
ventions were indicated if stenosis recurred. After
a follow-up of 6 months, BBD was considered
effective only if freedom from BS was complete
(complete resolution) or the remaining stenosis was
under 50% of bronchus diameter as viewed through
bronchoscope without stenosis-related symptoms
(partial resolution). BBD was considered ineffective
if other procedures were required because the
patient remained symptomatic (cough, dyspnea) or
a fall in pulmonary function tests was observed.Stent placement
Ultraflexs stents (Boston Scientific; Watertown;
MA, USA) were implanted as alternative therapy
when BBD was ineffective. All procedures were
performed by rigid bronchoscopy under general
anaesthesia. In these cases, BBD was performed
just prior to stent placement in those patients with
previous immediate improvement.
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Data in relation to: location of the stenosis (right
main stem bronchus (RMSB), left main stem
bronchus (LMSB), intermedius bronchus (IB) or
bilateral); initial improvement in BS after BBD;
evolution of respiratory function pre- and post
dilatation (FEV1, FVC and FEV1/FVC); improvement
of symptoms attributable to BS (cough, dyspnea);
and procedure complications were collected.Statistical analysis
In most cases values are shown as means7standard
deviation (X7SD). The study of differences between
qualitative variables was carried out using the
w2test and Fisher’s exact test when necessary. The
study of quantitative variables was established by
means of Student’s t-test for paired data. Po0:05
was considered significant. All data were analyzed
using the statistical package SPSS, version 11.0,
Chicago, IL.
This study was approved by the ethics committee
of Vall d’Hebron Hospital, Barcelona, Spain.Results
Nine out of 152 patients (5.9%) with LT (20 single
and 132 bilateral LT) were included (seven men,
with average age of 43.3719 years). In a total of 10
out of 284 anastomed airways (3.5%) BS was
detected (6 in IB, 3 in LMSB and 1 in RMSB) and
followed through for an average of 31.3724.5
months (range: 6–81). The rate of BS was similar
between patients with single or bilateral LT (3/20
vs. 6/132 patients; P ¼ 0:09); but in anastomed
airways it was higher in single than bilateral LT
(3/20 vs. 7/264 anastomed airways; P ¼ 0:02).
Average detection time for BS was 137773 days
(range: 64–274). Clinical features and follow-up
data are presented in Table 1.
The first FOB was performed in all patients at
15.8712 days (range: 3–38) following LT. Moderate-
severe ischemia was observed in 7 of the 10 suture-
lines (70%) which developed stenosis. Mild ischemia
was noted in one suture-line and no ischemia in the
other two suture-lines. The latter corresponded to
a patient with bilateral BS who required placement
of bilateral stent. In the 5 patients with bilateral LT
and one BS, ischemia was observed in all the
homolateral suture-lines of the bronchi which
developed stenosis and in two of the counterlateral
suture-lines.Bronchial balloon dilatation (BBD)
In the 10 BS a total of 33 BBD were performed
(mean 3.6772.6; range 1–8). Immediate improve-
ment in the stenosis, characterized by increased
luminal dimensions, was obtained in 31 (94%). Two
consecutive attempts at bronchial dilatation were
inefficacious in a patient with LMSB stenosis who
eventually required placement of an endobronchial
stent (patient 5). The study of pulmonary function
revealed a significant increase in absolute FVC
values after BBD interventions (2.170.8 L vs.
2.471.0 L, P ¼ 0:01). An increase in FEV1 values
was also observed but it was not significant
(1.470.8 L vs. 1.570.9 L, P ¼ 0:237). Improvement
in cough and dyspnea was observed in 6 of the 7
patients with stenosis-related symptoms.
Long-term follow-up showed effective results in
5 out of 9 (55%) stenosed bronchi with immediate
improvement in the stenosis with BBD. Complete
resolution of BS occurred in 3 of these after an
average of 2 BBD procedures (range 1–4). Partial
resolution was obtained in the other 2 patients
after an average of 7 BBD procedures (range 7–8)
without associated symptoms after 24 and 75
months of follow-up. In the remaining four BS
response to bronchial dilatation was ineffective
after an average of 3 BBDs (range 2–4) (patients 2,
4 and 7).
The BBD procedures were always well-tolerated
and with the exception of one slight hemorrhage
just after dilatation no complications were ob-
served secondary to the same.
Stent placement
Stent placement was required in 5 BS (unilateral BS
in 3 patients and bilateral BS in 1 patient). In a
patient with LMSB stenosis (patient 5), it was
indicated because BBD procedures were ineffica-
cious in achieving an immediate improvement of
BS. In the other 4 BS with initial efficacious BBD,
stent placement was performed because BS re-
appeared after a follow-up of 6 months. In the
latter cases, BBD was indicated just prior to stent
placement to make it easier.Comment
The findings of this study revealed a BS incidence of
3.5% of the bronchial anastomosis performed in LT
recipients, and IB was the most frequent site (60%
of cases). BBD proved to be a procedure with low
morbidity. It resulted in temporary improvement in
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J. De Gracia et al.32all cases except one and ensured maintenance of
optimal airway luminal dimensions in the long term
in half of them. It also proved useful in all cases in
which BBD was required prior to insertion of a
stent.
The pathogeny of BS secondary to LT has not
been clarified yet, although ischemic damage
(which affects the anastomosis area), rejection,
and infection have been considered as individual
and/or concomitant predisposing causes.15 Further-
more, the frequency of stenosis far from the
anastomosis (especially IB) is high and it leads us
to assume that local aspects play a relevant role in
its pathogeny. In this way, it is likely that deficient
vascularisation in this region plays a major role.
The insertion of rigid or self-expandable stents7,8
has been the most frequently used technique in the
management of tracheobronchial stenosis of benign
and malignant etiology. In LT patients, insertion of
self-expandable stents (Wallstents or Ultraflexs)
allows immediate and long-term maintenance of
optimal airway luminal dimensions in 80% and 45%
of cases, respectively.16 Nonetheless, several ad-
verse effects such as infections and/or granulation
tissue can be observed in over 60% of cases, similar
to the other causes of stenosis.7,8 Brachytherapy,
after the failure of other techniques, has been
proposed in few patients 17, with poor results.
In benign tracheobronchial stenosis not due to LT,
BBD has proved to be a straightforward technique.
Morbidity is low and it is useful in achieving
immediate and occasionally long-term increase of
airway luminal dimensions.1 Only a few studies
have evaluated BBD in LT patients and they
reported long-term variable efficacy (20–40%) and
major conclusions are difficult to reach because ofTable 2 Comparison of results in treating bronchial sten
study and other studies.
Authors Total
number
of BS
First-line
treatment
Numb
treate
BBD a
treatm
Sheski et al. 7 BBD 7 (10
Chhajed et al. 41 BBD or stent 31 (75
Colt et al. 6 BBD or stent 4 (40
Susanto et al. 12 BBD or stent 12 (10
Carre´ et al. 12 BBD or stent 8 (66
Ferretti et al. 10 BBD 10 (10
Orons et al. 32 BBD or stent 5 (15
De Gracia et al. 10 BBD 10 (10
BS: bronchial stenosis; BBD: bronchoscopic balloon dilatation.
This patient has been treated with laser too.differences in relation to methodology, indication,
evaluation and follow-up.2,5,9,10 In this way, the
present study showed optimal long-term results in
50% of cases, which is the highest reported to date
(Table 2). The results could be related to the
following: in this study the use of BBD was the first
therapeutic step in all cases; at least two BBD
sessions were performed if necessary; and alter-
native therapy was considered only if residual
stenosis was either over 50% of the bronchial
diameter or under 50% with related symptoms.
In this report and in others, IB was the most
frequent site of BS (60% of stenosis). In these cases,
the use of stents is controversial because stent
migration and right bronchial upper obstruction is
common.8,17 On the other hand, in our experience,
repeated BBD sessions avoid the need for further
treatment in 4 out of 6 cases during follow-up
(range 21–75 months) of the patients.
Safety of BBD was outstanding as described above
and prior to stent insertion it proved to be of great
efficacy and without associated morbidity, and
made stent placement easier. Its use must be first
choice over bougie dilatation by rigid broncho-
scope, a technique with greater associated mor-
bidity. Moreover, although more patients with
stenosis need stent placement, the complications
associated with its use in LT recipients are well
described2; therefore, it is desirable to limit its use
whenever possible. The results of this study
indicate that the use of BBD as first-line treatment
reduces both stent placements and the utilisation
of other techniques.
Our study has a certain bias. There is no control
group and no alternative techniques were discussed
due to the high ratio of complications secondary toosis secondary to lung transplantation in the present
er of BS
d with
s first-line
ent
Number of stent
placements/other
procedures due to
BBD failure
Number of BS
treated with
stent placement
as first-line
treatment
0%) 3 (42.8%)/2 (28.6%) 0
.6%) 23 (74.2%)/0 10 (24.4%)
%) 3 (75%)/2 (50%) 2 (20%)
0%) 7 (58.3%)/0 0
.7%) 4 (50%)/2 (25%) 4 (33.3%)
0%) 6 (60%) 0
.6%) 4 (80%)/0 27 (84.4%)
0%) 5 (50%)/0 0
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Balloon dilatation in lung transplantation 33the latter and the limited number of patients.
Furthermore, the absence of studies evaluating
efficacy of BBD, a low morbidity procedure accord-
ing to previous literature, as the first step in the
management of BS secondary to LT, encourages us
to design the study with BBD as elective technique
in these patients. Consequently, it has not been
possible to deal with some topics such as better
survival times in patients treated only with BBD.
Further studies with a greater number of cases are
required to confirm this.
In conclusion, this study suggests that BBD is a
procedure with low morbidity and of acceptable
efficacy in the long term. It must be seriously
considered as first choice procedure in BS of LT
patients. Two or more sessions could be necessary
until stable increase of airway luminal dimensions
is obtained.Acknowledgments
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